List of Excipients in Branded Drug AMOXAPINE

Generic Drugs Containing AMOXAPINE

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	amoxapine	0591-5713	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Actavis Pharma Inc	amoxapine	0591-5713	MAGNESIUM STEARATE
Actavis Pharma Inc	amoxapine	0591-5713	STARCH, CORN
Actavis Pharma Inc	amoxapine	0591-5713	STEARIC ACID

What are the Most Frequently-Used Excipients in AMOXAPINE?

# Of NDCs	Excipient
1	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
2	DIBASIC CALCIUM PHOSPHATE DIHYDRATE

Amoxapine Excipient Strategy and Commercial Opportunities: Generic Formulation, Regulatory, and Patent Analysis

Last updated: August 9, 2026

Amoxapine is an off-patent tricyclic antidepressant with limited current commercial scale and a largely generic supply base. The strongest formulation opportunities are low-cost, high-reliability oral solid dosage forms, orally disintegrating tablets, and liquid products for patients who cannot swallow tablets. The main technical risks are content uniformity at lower strengths, poor aqueous solubility, dose-related adverse effects, and limited market demand.

What is the commercial and regulatory status of amoxapine?

Amoxapine is a dibenzoxazepine tricyclic antidepressant originally marketed in the United States as Asendin. The FDA approved amoxapine tablets in 1980 under NDA 017874. The product is indicated for depressive illness and has also been associated with risks typical of tricyclic antidepressants, including cardiac toxicity, seizures, anticholinergic effects, and fatal overdose risk [1].

The U.S. product is available primarily as generic tablets in 25 mg, 50 mg, 100 mg, and 150 mg strengths. The product has no biologic component, so biosimilar regulation is irrelevant. Competition is governed by the ANDA pathway rather than a biosimilar pathway.

Commercial attribute	Amoxapine position
Therapeutic class	Tricyclic antidepressant
Original brand	Asendin
Original U.S. approval	1980
U.S. dosage form	Immediate-release tablets
Common strengths	25 mg, 50 mg, 100 mg, 150 mg
FDA pathway for competitors	ANDA, or 505(b)(2) for materially different products
Biosimilar exposure	None
Current branded exclusivity	None identified
Primary competitive basis	Price, supply reliability, quality, and dosage-form availability
Principal formulation opportunity	Low-cost immediate-release tablets with improved manufacturability

The commercial market is mature and likely small relative to newer antidepressants. The opportunity is therefore less dependent on premium pricing and more dependent on reducing manufacturing cost, maintaining supply, and addressing underserved dosage-form needs.

What patents protect amoxapine, and when did amoxapine lose exclusivity?

Amoxapine’s original active-ingredient and branded-product exclusivity expired decades ago. The commercial product is not protected by a current composition-of-matter patent that would prevent ordinary generic tablet competition.

The FDA Orange Book is the central source for listed patents and exclusivity associated with approved drug products. Amoxapine’s present market position is consistent with an off-patent generic drug rather than a product protected by an active Orange Book patent or regulatory exclusivity period [2].

Patent and exclusivity timeline

Event	Approximate timing	Commercial effect
Original amoxapine development and patenting	1970s	Created the original branded product position
FDA approval of Asendin	1980	Established U.S. regulatory approval
Original patent and market exclusivity period	Expired decades ago	Opened the market to generic competition
Generic tablet approvals	Subsequent decades	Created a multi-source market
Current market	Present	Primarily generic and price-sensitive

No current patent estate is known to create a material barrier for conventional amoxapine tablets. Any newly filed patent would need to cover a specific formulation, manufacturing process, delivery system, or clinical use. A patent directed only to amoxapine as an active ingredient would face substantial novelty and obviousness challenges.

What is the Orange Book status of amoxapine?

Amoxapine is regulated as an approved small-molecule drug. The relevant competitive pathway is an ANDA referencing the listed drug, subject to pharmaceutical equivalence, bioequivalence, manufacturing controls, labeling requirements, and current good manufacturing practice standards [2, 3].

The practical Orange Book implications are:

• Generic applicants can rely on the established safety and efficacy findings of the reference product.
• A conventional immediate-release tablet generally does not require a new clinical efficacy program.
• A formulation with a different dosage form, release profile, route, or clinically meaningful labeling difference may require a 505(b)(2) application.
• A Paragraph IV certification is commercially relevant only if the reference product has a listed patent. For a mature amoxapine tablet product without a blocking Orange Book patent, a Paragraph IV challenge is unlikely to be the main entry mechanism.
• A formulation applicant should review the current Orange Book, approved labeling, reference-product designation, and any listed patents before filing.

What excipients are used in amoxapine tablets?

Commercial amoxapine tablets use conventional oral-solid excipients. Labeling for marketed products identifies inactive ingredients that can vary by manufacturer and strength. Typical categories include diluents, binders, disintegrants, lubricants, glidants, and colorants [4].

A formulation developer should expect to manage:

Excipient function	Candidate classes	Relevance to amoxapine
Diluent	Lactose, microcrystalline cellulose, dibasic calcium phosphate, mannitol	Controls tablet weight, compressibility, and cost
Binder	Povidone, copovidone, pregelatinized starch, hydroxypropyl cellulose	Supports granule strength and low-dose uniformity
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid tablet breakup
Lubricant	Magnesium stearate, sodium stearyl fumarate	Controls ejection force and sticking
Glidant	Colloidal silicon dioxide	Improves powder flow
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Improves appearance, handling, and light protection
Sweetener or flavor	Sucralose, aspartame, flavors	Relevant to orally disintegrating or liquid products

The final selection must be based on compatibility, dissolution, impurity formation, stability, process capability, and the permitted inactive-ingredient exposure for the intended route.

Which excipient strategy is best for immediate-release amoxapine tablets?

A conventional immediate-release tablet remains the lowest-risk commercial strategy. The formulation should prioritize content uniformity, rapid disintegration, robust dissolution, and low manufacturing cost.

Direct compression

Direct compression can reduce processing steps and eliminate solvent-drying operations. A formulation based on microcrystalline cellulose, a suitable co-processed excipient, crospovidone, colloidal silicon dioxide, and a low-level lubricant may provide a practical platform.

The key risks are poor flow, segregation, punch sticking, and inadequate blend uniformity. These risks increase when the active drug represents a small fraction of total tablet weight, particularly for 25 mg tablets.

Wet granulation

Wet granulation may provide stronger control over flow and content uniformity. It can be useful where amoxapine has poor powder flow or where direct compression produces excessive weight variation.

The tradeoffs are higher capital and operating costs, longer processing time, and potential exposure to moisture and heat. The process requires control of granulation endpoint, drying temperature, residual moisture, and lubricant blending.

Dry granulation

Roller compaction can reduce water exposure while improving flow and density. It may be appropriate if wet granulation affects stability or if the active ingredient has poor flow characteristics. The main risks are overcompaction, slower dissolution, and variability in ribbon density.

Suggested development target

For an ANDA-oriented product, the most commercially attractive target is a bioequivalent immediate-release tablet that:

1. Uses widely accepted excipients.
2. Avoids novel excipient status.
3. Matches the reference product’s strength and release profile.
4. Demonstrates rapid and discriminatory dissolution.
5. Supports multiple strengths on one manufacturing platform.
6. Uses common packaging and standard film coating.
7. Maintains a low tablet count and competitive cost of goods.

What excipient issues affect low-dose amoxapine tablets?

The 25 mg strength creates the greatest content-uniformity challenge. A low drug load can produce segregation during transfer, compression, or hopper discharge. The risk is increased by differences in particle size, density, electrostatic behavior, and surface morphology between amoxapine and the excipient blend.

Manufacturing controls should include:

• Particle-size control for the active pharmaceutical ingredient.
• Defined preblend time and order of addition.
• Geometric dilution or granulation where needed.
• Blend-uniformity sampling based on process understanding.
• Hopper and feeder studies.
• In-process tablet-weight and hardness monitoring.
• Assay and content-uniformity testing across the compression run.

A formulation that performs well at 100 mg and 150 mg may not transfer directly to the 25 mg strength. The lower strength often requires a separate blend design or a common granulation with carefully controlled tablet weight.

What formulations are protected or commercially available for amoxapine?

The established commercial dosage form is the immediate-release tablet. A new product could pursue a differentiated formulation, but differentiation does not automatically create a strong patent position.

Orally disintegrating tablets

An orally disintegrating tablet could target patients with dysphagia, psychiatric patients with poor medication adherence, and caregivers administering medication in supervised settings. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and taste-masking systems are common development tools.

The principal challenges are:

• Bitter or metallic taste.
• Mechanical fragility.
• Moisture sensitivity.
• Dose uniformity.
• Packaging cost.
• Need to demonstrate rapid disintegration without compromising bioequivalence.

A meaningful patent position would need to cover a specific composition, particle engineering approach, taste-masking system, or manufacturing process rather than the concept of an orally disintegrating amoxapine tablet alone.

Oral solution or suspension

A liquid product could serve patients unable to swallow tablets. Amoxapine’s aqueous solubility is a major development issue. A true solution may require pH adjustment, cosolvents, surfactants, or complexation. Those systems create risks involving precipitation after dilution, preservative effectiveness, taste, chemical stability, and dose measurement.

An oral suspension may be easier than a solution if the active ingredient is sufficiently stable as a dispersed solid. It would require control of sedimentation, redispersibility, particle size, microbial quality, and dose uniformity.

A liquid product would likely be more suitable for a 505(b)(2) strategy if it cannot qualify as a straightforward generic equivalent to the listed tablet.

Modified-release tablets

Modified release could reduce dosing frequency, but the commercial rationale is uncertain. Amoxapine already belongs to an older class with a relatively limited prescribing base. A modified-release product would need to show a clear clinical or adherence benefit and manage dose dumping, food effects, alcohol effects, and exposure to active metabolites.

Hydrophilic matrix systems using hypromellose or similar polymers are technically feasible. They would require extensive dissolution characterization across pH conditions and agitation speeds. A modified-release product would face a higher regulatory and development burden than an immediate-release ANDA.

How strong is the amoxapine patent estate?

The legacy patent estate is weak from a current market-exclusion perspective. Amoxapine has no apparent active composition-of-matter barrier, no biologic exclusivity, and no high-value branded delivery platform.

A new patent estate could be built around:

• Amoxapine particle-size distributions.
• Amorphous or crystalline forms.
• Solid dispersions.
• Taste-masked particles.
• Orally disintegrating compositions.
• Stable liquid formulations.
• Modified-release matrices.
• Packaging systems that control moisture or light.
• Specific combination therapies or dosing regimens.

The strength of those claims would depend on unexpected technical results, reproducibility, enablement, and freedom from prior-art disclosures. A broad claim to “amoxapine plus pharmaceutical excipients” would likely be commercially weak. Narrow claims supported by comparative dissolution, stability, taste, or bioavailability data would have better defensive value.

What generic entry risks exist for amoxapine?

Generic entry risk is high because the product is old, the dosage form is conventional, and the reference product does not appear to have a meaningful current exclusivity barrier.

The main risks for an incumbent or new entrant are operational rather than patent-based:

• Active ingredient supply interruption.
• Failure to meet dissolution or content-uniformity specifications.
• Manufacturing-site changes.
• FDA warning letters or product recalls.
• Low-volume production economics.
• Limited supplier interest in amoxapine API.
• Concentration of market share among a small number of manufacturers.
• Substitution by newer antidepressants.

For a new entrant, supply reliability may be more valuable than formulation novelty. A manufacturer that can maintain uninterrupted availability across all four strengths may obtain commercial leverage even without a differentiated patent.

Which companies are challenging or competing with amoxapine?

Competition comes primarily from generic manufacturers and wholesalers rather than branded innovators. The relevant competitors include companies holding approved ANDAs or supplying amoxapine tablets through U.S. distribution channels. The market can change as suppliers enter, discontinue products, or transfer approvals.

The competitive set also includes therapeutic substitutes:

• Selective serotonin reuptake inhibitors.
• Serotonin-norepinephrine reuptake inhibitors.
• Atypical antidepressants.
• Other tricyclic antidepressants.
• Generic psychiatric products with once-daily dosing or lower overdose toxicity.

This substitution pressure limits the pricing power of a conventional amoxapine tablet. A differentiated dosage form must solve a specific access or adherence problem to justify a premium.

What patent litigation and Paragraph IV risks affect amoxapine?

No major current patent litigation involving the conventional U.S. amoxapine tablet market is identified in the principal FDA and public regulatory sources. Because the product is mature and lacks an apparent blocking patent estate, Paragraph IV litigation is not expected to define market access.

A new formulation patent could create litigation exposure if it becomes listed against a 505(b)(2) reference product or if a generic applicant seeks approval for a product that falls within the claims. Litigation risk would be highest for:

• Modified-release products.
• Novel liquid formulations.
• Patented solid-state forms.
• Taste-masked oral-dispersible systems.
• Combination products.

A product relying only on expired active-ingredient patents would have little litigation leverage.

How does amoxapine compare with other tricyclic antidepressants?

Factor	Amoxapine	Amitriptyline	Nortriptyline	Doxepin
Patent status	Mature generic	Mature generic	Mature generic	Mature generic, with some newer dosage-form activity
Main dosage forms	Immediate-release tablets	Tablets, capsules, liquid in some markets	Capsules, tablets, liquid in some markets	Capsules, tablets, topical and low-dose products
Formulation opportunity	ODT, liquid, supply reliability	Broad generic scale	Liquid and capsule supply	Low-dose and topical differentiation
Market size potential	Limited	Larger	Moderate	Segment-dependent
Key technical issue	Low-dose uniformity and solubility	Taste, low-dose products	Liquid stability and supply	Dose-form segmentation
Patent-based upside	Low to moderate for novel delivery	Low for standard products	Low for standard products	Higher where newer dosage forms exist

Amoxapine has less obvious commercial upside than drugs with large active patient populations or established modified-release markets. Its opportunity is narrower but may be attractive where competitors have discontinued low-volume strengths.

What revenue exposure and commercial opportunities exist?

Amoxapine revenue exposure is likely concentrated in a small generic market. Public company disclosures generally do not isolate amoxapine sales, so product-specific revenue estimates cannot be treated as reliable without transaction-level data.

Commercial opportunities fall into four categories:

1. Reliable generic supply. Maintain all strengths, reduce backorders, and serve institutional and specialty-pharmacy demand.
2. Orally disintegrating tablet. Address swallowing difficulty and supervised administration.
3. Oral liquid or suspension. Serve patients unable to use tablets, subject to solubility and stability feasibility.
4. Contract manufacturing and licensing. Develop a formulation and license the ANDA or 505(b)(2) product to a generic distributor with established channel access.

A standard immediate-release tablet is the lowest-risk product but offers limited pricing power. A novel dosage form can support a better margin, but only if it produces a measurable clinical or handling benefit and avoids excessive packaging and regulatory costs.

What FDA regulatory strategy applies to new amoxapine products?

For a conventional tablet, the preferred route is an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference listed drug. The formulation should use established excipients at levels consistent with FDA precedent and the inactive-ingredient database [3, 5].

A 505(b)(2) application becomes more relevant when the product changes:

• Dosage form.
• Route of administration.
• Release mechanism.
• Strength or dosing regimen.
• Excipients in a way that affects clinical performance.
• Labeling supported by literature or new clinical data.

A liquid, orally disintegrating, or modified-release product may require additional pharmacokinetic, food-effect, alcohol-interaction, stability, or clinical bridging work. The regulatory pathway should be selected before excipient screening because the reference-product and bioequivalence strategy will determine the acceptable formulation space.

Key Takeaways

• Amoxapine is an old, off-patent small-molecule antidepressant marketed mainly as generic immediate-release tablets.
• Conventional tablet competition faces little current patent or exclusivity protection.
• The best low-risk strategy is a robust immediate-release tablet platform covering 25 mg, 50 mg, 100 mg, and 150 mg strengths.
• The 25 mg strength presents the greatest content-uniformity and segregation risk.
• Direct compression is attractive for cost, while wet or dry granulation may improve process robustness.
• Orally disintegrating tablets and oral liquids offer the clearest formulation differentiation.
• A liquid product must address amoxapine’s poor aqueous solubility, taste, stability, and dose-measurement requirements.
• Modified release is technically feasible but has a weaker commercial case and a higher regulatory burden.
• Patent value would come from a specific formulation, solid form, process, or delivery system, not from amoxapine itself.
• Supply reliability may be more commercially important than patent exclusivity in this small generic market.

FAQs

Can amoxapine be reformulated with a novel excipient?

Yes, but a novel excipient would increase regulatory complexity and safety-qualification requirements. Established pharmaceutical excipients are preferable for an ANDA-oriented product.

Is an amoxapine oral liquid commercially attractive?

It may address an underserved patient group, but solubility, taste, preservative effectiveness, and dose uniformity create substantial development risks. A suspension may be more practical than a true solution.

Would an amoxapine orally disintegrating tablet require a new patent?

Not necessarily. It could be filed as a product without patent protection, but a commercial premium would be easier to defend with claims covering a specific taste-masking or fast-disintegration composition.

Does amoxapine have biosimilar competition?

No. Amoxapine is a chemically synthesized small molecule, so competitors use generic-drug regulatory pathways rather than the biosimilar pathway.

Can an amoxapine formulation support a 505(b)(2) application?

Yes. A materially different liquid, modified-release, or other dosage form may qualify for a 505(b)(2) application if the sponsor can bridge the new product to the established amoxapine safety and efficacy record.

References

1. U.S. Food and Drug Administration. (1980). Asendin (amoxapine) prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA) process.
4. DailyMed. (n.d.). Amoxapine tablet labeling and inactive ingredients. National Library of Medicine.
5. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database.